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Abstract: Colposcopy is often used in follow-up after treatment for cervical intraepithelial neoplasia
(CIN) despite its marked inter-observer variability and low sensitivity. Our objective was to assess
the role of colposcopy in post-treatment follow-up in comparison to hrHPV (high-risk human
papillomavirus) testing, cytology, and cone margin status. Altogether, 419 women treated for
histological high-grade lesion (HSIL) with large loop excision of the transformation zone (LLETZ)
attended colposcopy with cytology and hrHPV test at six months. Follow-up for recurrence of
HSIL continued for 24 months. Colposcopy was considered positive if colposcopic impression
was recorded as high grade and cytology if HSIL, ASC-H (atypical squamous cells, cannot exclude
HSIL), or AGC-FN (atypical glandular cells, favor neoplasia) were present. Overall, 10 (10/419, 2.4%)
recurrent HSIL cases were detected, 5 at 6 months and 5 at 12 months. Colposcopic impression was
recorded at 407/419 6-month visits and was positive for 11/407 (2.7%). None of them had recurrent
lesions, resulting in 0% sensitivity and 97% specificity for colposcopy. Sensitivity for the hrHPV
test at 6 months was 100% and specificity 85%, for cytology 40% and 99%, and for margin status at
treatment 60% and 82%, respectively. While the hrHPV test is highly sensitive in predicting recurrence
after local treatment for CIN, colposcopy in an unselected population is not useful in follow-up after
treatment of CIN.
Keywords: colposcopy; CIN; follow-up; test of cure
1. Introduction
Cervical cancer develops from precursor lesions called cervical intraepithelial neoplasia (CIN),
which can be treated before their progression into cancer [1]. The most common treatment modality
for CIN today is a large loop excision of the transformation zone (LLETZ) [2]. Not all high-grade CIN
lesions warrant treatment [3] and the number of annual CIN treatments in different countries is heavily
influenced by national screening and treatment practices [4] In 2017, the incidence of histological
high-grade lesions HSIL (CIN 2/3) in Finland was 74/100,000 women [5], while the incidence of annual
treatments in women aged 21–30 years in the US was estimated to be over 600/100,000 women [4].
Treatment of CIN is effective in preventing subsequent invasive cervical cancer, but women treated
for CIN remain at increased risk of developing new CIN compared to the general population [6].
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The majority of cases develop within the first two years after treatment [7,8] and approximately 7% of
treated women are diagnosed with recurrence during the 18-month follow-up period [9]. Large lesion
size and increasing histopathological grade of the lesion, smoking, older age of the patient, involved
cone margins, and hrHPV (high-risk human papillomavirus) persistence have been detected as risk
factors that predict recurrence [10–12]. Furthermore, compared to the general population, the risk for
cervical cancer after treatment for CIN is increased for at least 25 years [11,13–15].
The presence or absence of hrHPV is an accurate method to predict treatment failure or cure [9,
16–18] also when compared to cytology and margin status [19–22]. Furthermore, affected, or positive,
resection margins of the excised cone are associated with an increased risk of treatment failure [12,22],
while a recent meta-analysis found the subsequent hrHPV test to be the most accurate method to
predict treatment outcome [9].
In some countries, including Finland and Germany, colposcopy is still included in the primary
follow-up in national guidelines [23,24]. However, the role and added value of colposcopy in follow-up
has rarely been studied. Old studies present conflicting results [25–27]: Others stating that colposcopy
does not significantly improve the sensitivity of cytology in early post-treatment follow-up [27] while
others report 100% sensitivity for colposcopy for residual disease [25]. Additionally, colposcopy has
adverse psychological effects, including anxiety, distress, and a negative effect on sexual function [28].
UK guidelines recommend hrHPV at 6 months as a test of cure (TOC) but do not present evidence on
the role of colposcopy [29]. The European guidelines recommend follow-up at 6, 12, and 24 months
but do not define the role of colposcopy in the follow-up [30]. The American guidelines recommend
hrHPV as a TOC at six months after treatment regardless of cone margins but outlines follow-up at six
months with colposcopy as acceptable, especially for those with positive margins [31].
HrHPV testing has been well established as the gold standard TOC after treatment of CIN, but the
evidence on the value of colposcopy in the follow-up, especially when resection margins are positive,
is still lacking. The aim of our study was to assess the value of colposcopy in follow-up after local
excisional treatment, by comparing the diagnostic accuracy of the margin status at treatment and
colposcopy, cytology, and hrHPV test at six months in predicting HSIL recurrence after local excisional
treatment. Furthermore, we aimed to explore the value of colposcopy in women with positive margins.
2. Results
Characteristics of the study cohort are shown in Table 1. The mean age of the patients at the time
of treatment was 35.1 years (range 20.1–76.6). Smoking status at LLETZ or at 6 months was available
for 393/419 (93.8%) cases, and more than one-third were smokers (143/419, 35.8%). Of the non-smokers
233/419 (64.2%) majority had never smoked (217/233, 93.1%). In 105 cases of the 419 (25.3%), LLETZ
was performed at the first visit (select and treat), either due to suspicion of HSIL lesion, or due to the
presence of the type 3 transformation zone (TZ3) along with a high-grade referral cytology, according
to the Finnish current care guidelines [23]. Otherwise, the indication for the LLETZ procedure was
persistent CIN1 (low-grade histological lesion, cervical intraepithelial lesion grade 1) in 1.7% (7/419),
CIN2 (cervical intraepithelial neoplasia grade 2) for 40 % (165/419), CIN3 (cervical intraepithelial
neoplasia grade 3) for 29.6% (123/419), and AIS (adenocarcinoma in situ) for 0.2% (1/419). Two patients
(2/419, 0.4%) had both AIS and CIN3 in biopsies.
At the six-month visit, punch biopsies were taken of 303/419 (72.3%) of the women. At 12 months,
70 out of 419 attended a follow-up visit, 45 out of 419 at 18 months, and 298 out of 419 at 24 months,
with follow-up data available. At 24 months, nearly one-third (121/419, 28.9%) were lost to follow-up.
Overall, only 10 women (10/419, 2.4%) developed residual or recurrent histological HSIL lesions
during the 24-month follow-up period. Five of them were diagnosed at six months and an additional
five cases at 12 months after the LLETZ.
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Table 1. Demographics.
Main (n = 419) All (n = 491)
Mean age
(SD 8.4)
35.1
(20.1–76.6)
Mean age
(SD 9.3)
36.3
(20.1–76.6)
n (%) n (%)
Smoking Smoking
Yes 143 (34.1) Yes 168 (34.2)
No 250 (59.7) No 293 (59.7)
NA 26 (6.2) NA 30 (6.1)
Total 419 (100.0) Total 491 (100.0)
Indication for
LLETZ
Worst
histology n (%)
Indication for
LLETZ
Worst
histology n (%)
Persistent
LSIL/CIN1 7 (1.7) CIN2 5 (71.4)
Persistent
LSIL/CIN1 8 (1.6) CIN1 1 (12.5)
CIN3 2 (28.6) CIN2 5 (62.5)
CIN3 2 (25)
HSIL/CIN2 165 (40.0) CIN2 121 (73.3) HSIL/CIN2 165 (34.0) CIN1 0 (0.0)
CIN3 44 (26.7) CIN2 118 (71.5)
CIN3 47 (28.5)
HSIL /CIN3 123 (29.6) CIN2 2 (1.6) HSIL/CIN3 134 (27.6) CIN1 0 (0.0)
CIN3 121 (98.4) CIN2 1 (0.7)
CIN3 133 (99.3)
AIS 1 (0.2) AIS 1 (100) AIS 3 (0.6) CIN1 0 (0.0)
CIN2 0 (0.0)
CIN3 1 (33.3)
AIS 3 (100)
CIN3 and AIS 2 (0.5) CIN3 2 (100) CIN3 and AIS 2 (0.4) CIN1 0 (0.0)
AIS 1 (50) CIN2 0 (0.0)
CIN3 2 (100)
AIS 1 (50)
Select andtreat * 105 (25.3) CIN2 37 (35.2) Select andtreat * 154 (31.7) CIN1 7 (4.5)
CIN3 68 (64.8) CIN2 41 (26.6)
AIS 1 (1.0) CIN3 89 (57.8)
AIS 6 (39.0)
Other ** 15 (9.7)
Other ***** 12 (2.9) CIN2 7 (58.2) Other *** 20 (4.1) CIN1 2 (10)
CIN3 5 (41.7) CIN2 7 (35)
AIS 2 (16.7) CIN3 4 (20)
AIS 3 (15)
Other **** 5(25)
NA 5(1.2) NA 5/1.2)
Total 419 (100.0) Total 491 (100.0)
SD, standard deviation, LLETZ large loop excision of the transformation zone, LSIL/CIN1, low-grade squamous
intraepithelial lesion, grade 1, AIS adenocarcinoma in situ, NA not available. * select and treat (cytology ASC-H
(atypical squamous cells, cannot exclude HSIL), HSIL (high-grade squamous intraepithelial lesion) or AGC-FN
(atypical glandular cells, favor neoplasia) and colposcopic impression of HSIL or TZ3 (transformation zone type 3))
** Normal histology 8, LSIL 6, adenocarcinoma 1 *** 11 Discrepancies, 2 referral cytology + histology, 1 postcoital
bleeding, 6 atypia in columnar cells **** 5 LSIL ***** 2 atypia in columnar cells, 7 discrepancies, 1 post-coital bleeding,
2 referral cytology + histology.
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The colposcopic assessment was available for 407/419 (97.1%) of the 6-month visit. Colposcopy
was considered positive in 11/407 (2.7%), but none of them had HSIL histology in biopsies. Colposcopy
was considered negative in 396/407 (97.3%) women at 6 months, but 9 of them 9/396 (2.3%) had
HSIL in random biopsies, 5 at the 6-month visit, and 4 at the 12-month visit. For one recurrent case,
the colposcopic assessment was not available (Table 2). Colposcopic suspicion of high-grade lesion
performed poorly as a TOC at six months (sensitivity 0 %, specificity 97 %, PPV 0 %, and NPV 98 %)
(Table 3).
Table 2. Recurrence of HSIL for women with HSIL as worst histology, repeat LLEZT excluded.
n/N (%) * 6 Monthsn/N (%)
12 Months
n/N (%)
18 Months
n/N (%)
24 Months
n/N (%)
All Cumulative
n/N (%)
Overall HSIL
(n = 419) 5/419(1.2) 5/70 (6.6) 0/45 (0.0) 0/298 (0.0) 10/419 (2.4)
Colposcopy at 6
months ** (n = 407) (n = 407) (n = 66) (n = 42) (n = 288) (n = 407)
+11/407 (2.7) 0/11 (0.0) 0/3 (0.0) 0/0 (0.0) 0/7 (0.0) 0/12 (0.0)
−396/407 (97.3) 5/396 (1.3) 4/63 (6.3) 0/42 (0.0) 0/267 (0.0) 9/396 (2.3)
Cytology at 6 months
*** (n = 418) (n = 418) (n = 70) (n = 43) (n = 284) (n = 418)
+6/418 (1.4) 4/6 (66.7) 0/4 (0.0) 0/0 (0.0) 0/2 (0.0) 4/6 (57.2)
−412/418 (98.6) 1/412 (0.2) 5/66(7.6) 0/43 (0.0) 0/282 (0.0) 6/412 (1.5)
HrHPV at 6 months
(n = 407) (n = 407) (n = 69) (n = 39) (n = 277) (n = 407)
+72/407 (17.7%) 4/72 (5.6) 5/58 (8.6) 0/17 (0.0) 0/31(0.0) 9/72 (12.5)
−335/407 (82.3) 0/335 (0.0) 0/11 (0) 0/22 (0.0) 0/246 (0.0) 0/355 (0)
* n = cases of histological HSIL, N = cases assessed ** Colposcopy was considered positive if colposcopic assessment
was HSIL *** Cytology was considered positive is ASC-H (atypical squamous cells, cannot exclude HSIL), HSIL
(high-grade cervical intraepithelial lesion) or AGC-FN (atypical grandular cells, favor neoplasia) was present.
LLETZ large loop excision of the transformation zone
Table 3. Comparison of different tests of cure at 6 months and margin status at LLEZT to predict
recurrence of HSIL lesions at 24-month follow-up. Recurrence of HSIL overall at 24 months was 2.4%.
Test of Cure Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Colposcopy 0.00 (0.00–0.30) 0.97 (0.95–0.98) 0.00 (0.00–0.24) 0.98 (0.96–0.99)
Cytology 0.40 (0.17–0.69) 0.99 (0.98–1.00) 0.67 (0.30–0.94) 0.99 (0.97–0.99)
HrHPV 1.00 (0.70–1.00) 0.85 (0.81–0.88) 0.12 (0.07–0.22) 1.00 (0.99–1.00)
Margins 0.60 (0.31–0.83) 0.82 (0.78–0.85) 0.08 (0.03–0.15) 0.99 (0.97–1.00)
PPV = positive predictive value, NPV = negative predictive value CI confidence interval, HrHPV high-risk
human papillomavirus.
A cytology result at 6 months was available for 418/419 (99.8%) women. Cytology was considered
negative for 412/418 (98.6%) of patients and positive for 6/418 (1.4%) of patients. Altogether, 6/412,
(1.5%) of the women with negative cytology had recurrence: One at 6 months and 5 at the 12-month
follow-up visit. Of the cytology-positive women, 4/6 (57.2%) developed a recurrent disease, all of
them at 6 months. (Table 2). Cytology at a cut-off of HSIL resulted in sensitivity of 40%, specificity of
99%, PPV of 67%, and NPV of 99% (Table 3). In a sensitivity analysis including all women (n = 491),
using LSIL as the cytology threshold and LSIL (CIN1+) histology as the outcome, the cytology result
was available for 490/491 (99.8%) women. Cytology was negative for 473/490 (96.5%) and 26 of them
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(26/473 (5.7%)) had recurrent histological LSIL. Cytology was positive for 17/490 (3.5%) women and
7/17 (41.2%) had recurrent LSIL.
HrHPV test data were available for 407/419 (97.1%) at 6 months. Altogether, 335/407 (82.3%)
women were HrHPV negative at 6 months after LLETZ and none of them developed recurrent
disease during the 24-month follow-up. HrHPV was positive for 72/407 (17.7%) at 6-month visits
and 9/74 (12.5%) developed recurrent disease. Four recurrent lesions were detected at 6 months and
5 at 12 months. In one recurrent case, the hrHPV test result was missing (Table 2). HrHPV testing
performed best as the diagnostic test of cure, with a sensitivity of 100%, specificity of 85%, NPV of 100%,
and PPV of 12% (Table 3). All women with recurrence were hrHPV positive at 6 months but colposcopic
impression was negative, indicating that colposcopy performs poorly on HrHPV-positive women.
Surgical resection margins were free of HSIL for 339/419 (80.9%) of the cases. Among women with
free resection margins, recurrent HSIL was detected in 4/339 (1.2%), 2 at 6 months and 2 at 12 months.
Surgical margins were affected in 80/419 (19.1%) of cones and 6/80 (7.5%) had recurrence, 3 at 6 months
and 3 at 12 months (Table 4). The margin status of the first cone as a predictor of recurrent lesion
resulted in a sensitivity of 60%, specificity of 82%, PPV of 8%, and NPV of 99% (Table 3).
Table 4. Recurrence of HSIL lesions during the 24-month follow-up after LLETZ: according to the
resection margin status of the first LLETZ and separately for all women regardless for histopathology
and according to whether reoperation for affected margins was performed.
Margins Affected Margin Status 6 Monthsn/N (%) *
12 Months
n/N (%)
18 Months
n/N (%)
24 Months
n/N (%)
All Cumulative
n/N (%)
Any Margin
No re-LLETZ, only
HSIL (n = 419) Free (n = 339) 2/339 (0.6) 2/51 (3.9) 0/28 (0.0) 0/236 (0.0) 4/339 (1.2)
Affected (n = 80) 3/80 (3.8) 3/19 (15.8) 0/15 (0.0) 0/47 (0.0) 6/80 (7.5)
All LLETZ (n = 491) Free (n = 368) 2/368 (0.5) 2/56 (3.6) 0/36 (0.0) 0/249 (0.0) 4/368 (1.1)
Affected (n = 123) 3/123 (2.4) 3/26 (11.5) 0/23 (0.0) 0/74 (0.0) 6/123 (4.9)
No re-LLETZ Affected (n = 85) 2/85 (2.4) 3/20 (15) 0/16 (0.0) 0/469(0.0) 5/85 (5.8)
Re-LLETZ Affected (n = 38) 1/38 (2.6) 0/6 (0.0) 0/7 (0.0) 0/25 (0.0) 1/38 (2.6)
Ectocervical
margins (66/123)
All LLETZ Affected 2/66 (3.0) 3/12 (25) 0/15 (0.0) 0/40 (0.0) 5/66 (7.6)
No re-LLETZ Affected 2/53 (1.9) 3/10 (30) 0/11 (0.0) 0/29 (0.0) 4/52 (7.7)
Re-LLETZ Affected 0/13 (0.0) 0/2 (0.0) 0/4 (0.0) 0/11 (0.0) 1/14 (7.1.)
Endocervical
margins (37/123)
All LLETZ Affected 0/37 (0.0) 0/9 (0.0) 0/5 (0.0) 0/24 (0.0) 0/37 (0.0)
No re-LLETZ Affected 0/20 (0.0) 0/7 (0.0) 0/3 (0.0) 0/14(0.0) 0/20 (0.0)
Re-LLETZ Affected 0/17 (0.0) 0/3 (0.0) 0/2 (0.0) 0/10 (0.0) 0/17 (0.0)
Both Margins
(20/123)
All LLETZ Affected 1/20 (5) 0/3 (0.0) 0/3 (0.0) 0/10 (0.0) 1/20(5.0)
No re-LLETZ Affected 1/12 (9.1) 0/2 (0.0) 0/2 (0.0) 0/6 (0.0) 1/11 (9.1)
Re-LLETZ Affected 0/8 (0.0) 0/1 (0.0) 0/1 (0.0) 0/4 (0.0) 0/9 (0.0)
* n = cases of histological HSIL (high-grade cervical intraepithelial lesion), N = cases assessed, LLETZ large loop
excision of the transformation zone.
In all women, regardless of the initial histopathological grade of the treated lesion or if
reoperation was done, margins were affected for 123/491 (25.0%) women. Of the affected margins,
66/123 (53.7%) were ectocervical, 37/123 (30.1%) endocervical, and 12/123 (16.3%) had both margins
affected. Reoperation before the first follow-up visit was performed for 38/123 (26.8%) of those with
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affected resection margins. Of them, 13/38 (34.2%) had an affected ectocervical margin, 17/38 (44.7%)
endocervical margin, and for 8/38 (21.1%) both margins were affected in the original cone. In reoperation
cones, only 26.3% (10/38) had histological HSIL and any dysplasia was found only in 11 specimens
(11/38, 28.9%). For those patients with persistent histological lesion in reoperation, endocervical
margins were originally affected in 8/11 cases, ectocervical margins in 1/11, and both marginals in
2/11 cases.
Recurrent HSIL, excluding residual HSIL still present at possible reoperation, was detected in
6/123 (4.9%) women with affected margins during the follow-up. There were 5/66 (7.6%) recurrent cases
after affected ectocervical margins and 1/20 (5.0%) when both margins were affected. We detected no
recurrences (0/37) among women with affected endocervical margins (Table 3). Colposcopic impression
at 6 months was recorded for 121/123 of those with affected margins. Six women with affected
margins, with or without immediate retreatment before the first follow-up visit, had a recurrent HSIL
(6/121 5.0%). None of them were detected by colposcopic impression at six months.
Cigarette smoking did not affect the recurrence rate, as three recurrent cases were detected
(3/143 2.1%) among smokers and 6/250 (2.4%) among the non-smokers. All recurrent cases of the
non-smokers were among women who had never smoked.
3. Discussion
The diagnostic performance of colposcopic assessment alone at 6 months after LLETZ to predict
treatment outcome, i.e., recurrence of HSIL during the follow-up was poor. HrHPV testing alone at
6 months, on the other hand, was a reliable test of cure (TOC) to predict HSIL recurrence. Affected
margins were associated with recurrence but were not a good predictor of treatment failure alone.
Surprisingly, colposcopy was not useful either when assessing only those women with positive
resection margins. Furthermore, three quarters of repeated cones done for affected margins were free
of residual disease.
Even though colposcopy has now widely been abandoned in follow-up after LLETZ, to our
knowledge, this is one of the very rare studies where the added value of colposcopy after treatment
was assessed. Women treated for CIN have an increased risk of recurrence [2,11,32] and therefore
follow-up protocols after treatment need to identify women at risk. HrHPV testing has been shown in
several studies to be the most reliable test of cure after treatment of CIN [7,9,16,19,21,33]. Our study is
in concordance with these results, with the performance of the hrHPV test at 6 months being suitable as
a TOC alone to predict treatment success and to a lesser extent treatment failure. In only one recurrent
dysplasia case, the hrHPV test result was missing. Here, only 2.4% (10/419) of the treated HSIL cases
developed a residual or recurrent disease during the two-year follow-up period. This is a slightly
lower number than in previous reports [7,32,34]. According to the Finnish Current Care Guidelines,
women with negative hrHPV, cytology, and histology at 6 months are followed up with cytology and
the hrHPV test at 24 months. This explains the small number of women examined at 12 and 18 months
and could well explain the lower overall recurrence compared to other studies, where more intense
surveillance might result in the detection of lesions that are likely to regress spontaneously [4].
Finland has a very good track record in preventing cervical cancer, with an efficient nationwide
organized screening program since the 1963. This program includes colposcopy in a major role in
diagnosis, treatment, and follow-up of cervical dysplasia. Thus, the Finnish Guidelines have been very
cautious to make any major changes in the practices without good evidence. The results are based on a
prospective cohort setting and recruitment from everyday clinical practice from a single referral center,
thus making our results generalizable. Colposcopies were performed by certified colposcopists and all
of the samples were analyzed in a single referral laboratory.
The European guidelines recommend follow-up after treatment of CIN at 6, 12, and 24 months
but do not explicitly state what should be used as the TOC or what the role of colposcopy is [30].
The American guidelines recommend hrHPV as the test of cure but state that follow-up with colposcopy
is acceptable [31]. UK guidelines recommend hrHPV testing at 6 months as TOC. All guidelines refer
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to good results on hrHPV as a TOC but no references to the actual role or added value of colposcopy is
given. In Finland, colposcopy has traditionally been used as a TOC 6 months after LLETZ, even though
the inter-observer reproducibility of colposcopy is poor [35,36]. The performance of colposcopy as a
test of cure after LLETZ was poor here as well, and did not reliably identify the patients that developed
recurrent disease. After treatment, epithelialization or scarring of the cervix might appear, making
assessment of the transformation zone unreliable and likely leading to 303 patients having random-like
punch biopsies taken without apparent colposcopic impression of HSIL according to the national
guidelines, which were in effect during the study. Therefore, colposcopy, as a TOC, can be both time
and resource consuming and often lead to unnecessary biopsies [4]. Even though some publications
have endorsed random biopsies in primary diagnostics [37,38], no evidence has been presented in
follow-up. Thus, it is essential to abandon procedures and old practices that are not useful. Considering
also the psychological burden and anxiety inflicted by colposcopy [28,39,40] and adverse effects of
colposcopy and biopsies [41], unnecessary colposcopy could even be harmful and should not be used
as the primary tool in follow-up of treated patients. The likelihood of detecting histological HSIL is
much greater when performing colposcopy for HPV-positive women after treatment, whereas adverse
effects are likely to dominate if colposcopy is routinely performed for all women during follow-up.
Even though an affected margin status has been associated with treatment failure [8,12,42],
some studies [43] and a recent meta-analysis [9] found that margin status is not as accurate as hrHPV
to predict treatment failure. Here, the sensitivity of the margin status to predict treatment failure was
60% (95% CI 0.31–0.83), specificity 81% (95% CI 0.78–0.85), PPV 8% (95% CI 0.03–0.15), and NPV 99%
(95% CI 0.97–1.00). The corresponding numbers in the meta-analysis by Arbyn et al. were a sensitivity
of 55.8% (95% CI 45.8–65.5) and specificity of 84.4% (95% CI 79.5–88.4). Recurrence was highest among
those with affected margins (7.5%). The corresponding number in the meta-analysis by Arbyn et al.
was 17.1%. On the other hand, in the 38 women who had an immediate reoperation for affected
margins, only one-third had residual HSIL still present at the repeat cone. Of the six recurrent cases
with affected margins where immediate reoperation was not performed, five were hrHPV-positive at
6 months, and for one, hrHPV was not taken. All these six recurrent cases occurred in patients who had
affected ectocervical margins. This is contradictory to other studies, where the probability of recurrence
has been reported to be higher if the endocervical margin was affected [9,44], although in some studies
the risk of recurrent disease was the same irrespective which margin was affected [42,45]. A recent
register-based study reported women with involved margins to be at increased risk for recurrent
disease; however, the risk was not increased, if only the ectocervical margin was affected [20]. In our
study, almost half of the patients with positive endocervical margins had a repeated LLETZ versus
21 % of the cases who had an affected ectocervical margin, but our total numbers here are low and
conclusions should be prudent. This might explain the lower recurrence with affected endocervical
margins observed here. Still, most women who had immediate reoperation due to affected resection
margins did not present residual HSIL at the reoperation. Furthermore, all women with a positive
margin status and recurrent disease were hrHPV positive at 6 months. Furthermore, the histological
assessment of surgical margins might be hampered due to the thermal effect of the LLEZT, resulting
in interpreting a complete excision as incomplete [46]. On the other hand, even with clear margins,
residual disease might still be present within endocervical crypts or as skip lesions [15]. This warrants a
much more conservative approach towards reoperations for women with affected margins. Follow-up
with the hrHPV test and restriction of colposcopy for HPV-positive women only might be an acceptable
approach here as well. Repeated LLETZ procedures should perhaps be restricted to cases where there
is histological confirmation of residual disease or persistent hrHPV positivity after the treatment along
with affected margins, and these conclusions are supported by previous literature [9,20].
Our study has some limitations. Patients attended follow-up visits well, but we did lack some
follow-up data, reflecting the true clinical practice. The hrHPV status at 6 months was known for
116/121 of the women lost to follow-up at 24 months and 71.6% (83/116) of them were negative and
28.4% (33/116) positive, whereas overall only 17.7% of all women were hrHPV positive at six months.
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This might well lead to underestimation of the recurrence rate as women who were hrHPV positive at
six months were both at increased risk of recurrence as well as to loss to follow-up and perhaps explain
the lower recurrence observed here compared to some previous publications [7,9]. The follow-up lasted
for two years, before returning to the 5-year interval screening program. This duration of intensified
follow-up is generally considered to be sufficient, but still, a longer follow-up would be needed to
rule out late recurrences. The relatively high number of reoperations conducted on 38/123 women
with positive margins may also have influenced the total recurrence rate. However, in only 10/38 of
these women, CIN2+ was still present at reoperation and even when including these cases, the rate
of residual and recurrent cases would have been 4.4% (20/457). Additionally, in total, our numbers
of different positive margin statuses of ecto vs. endo are low and hence caution should be used to
draw conclusions.
4. Materials and Methods
This study was a part of a prospective cohort study (HELICOPTER study: ISRCTN10933736)
conducted at Helsinki University Hospital’s Outpatient Colposcopy Unit, Finland, between January
2014 and May 2016. The unit serves as the sole reference center in the Helsinki-Uusimaa region with
over 1.6 million residents. In this study, we included all women treated with LLETZ with at least six
months of follow-up after treatment (n = 491). The main study population comprised of women with
no repeated excisions and HSIL as the worst histology (n = 419) (Figure 1).
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Recurrence was defined as histologically confirmed HSIL (CIN2 or CIN3) or more severe lesion
at the 6-, 12-, or 24-month follow-up visits. Colposcopy was considered to be positive if colposcopic
impression, assessed by the colposcopist performing the procedure, was of high grade (HSIL), regardless
of whether histopathological samples (punch biopsies) were taken or not. Cytology was considered
to be positive if HSIL (high-grade squamous intraepithelial lesion), ASC-H (atypical squamous cells,
cannot rule out HSIL), or AGC-FN (atypical glandular cells, favor neoplasia) was detected. The margins
status of the excised cone was considered either free (negative) or affected (positive), depending on
whether the HSIL lesion extended to endocervical, ectocervical, or both margins. If the margin status
was reported as unclear, we considered the margins to be affected.
The performance of the hrHPV test, cytology, and colposcopy and cone margin status as tests of
cure were assessed in terms of their sensitivity, specificity, negative predictive value (NPV), and positive
predictive value (PPV) to detect recurrence within the follow-up. Differences in recurrence proportions
between different groups were assessed using Fisher’s exact test.
We repeated analyses including women with repeated excisions and all women regardless of
histopathological finding (n = 491), with additional sensitivity analysis using LSIL as a threshold for
cytology and histology. The performance of the margin status as a predictor of recurrence was also
analyzed separately for all women irrespective of histology and further stratified according to whether
reoperation was done or not. If an immediate reoperation was done for affected margins and HSIL
persisted in the second cone, persistent HSIL was not considered as a recurrent lesion. All results were
also additionally stratified according to smoking status.
All statistical analyses were done with IBM SPSS statistics (version 24). The study was approved
by Helsinki University’s Ethical Committee (130/13/03/03/2013, 24.4.2013) and written informed consent
was acquired from all participants.
5. Conclusions
In conclusion, colposcopy was not useful primarily in the follow-up of patients after treatment for
CIN—overall or when assessing patients with affected surgical margins only. The HrHPV test alone at
6 months is an accurate test of cure and colposcopy should be reserved for patients who are hrHPV
positive after treatment. Routine repeated LLETZ procedures due to affected cone margins should be
avoided and those patients primarily managed with active surveillance instead.
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